Safety and Effectiveness of CYP2C19 Genotype-Guided P2Y12 Inhibitor Therapy Compared to Standard Treatment After Complex Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
Led by Zunyi Medical College · Updated on 2024-03-20
1200
Participants Needed
1
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of selecting P2Y12 receptor inhibitors based on CYP2C19 genetic testing compared to conventional antiplatelet therapy in Chinese patients with acute coronary syndrome ACS undergoing complex percutaneous coronary intervention PCI. This trial aims to find the best balance between preventing blood clots and reducing bleeding risks by tailoring medication choices guided by a patients genetics.
Participants will initially receive dual antiplatelet therapy DAPT with either ticagrelor or clopidogrel plus aspirin before PCI. After PCI, patients are randomly assigned to a genotype-guided group, where treatment depends on their CYP2C19 gene variant ticagrelor or clopidogrel plus aspirin for 3 months, or a conventional group receiving standard DAPT. Following 3 months, both groups continue with a single P2Y12 inhibitor either ticagrelor or clopidogrel without aspirin for an additional 9 months.
Throughout the 12-month study, participants will be monitored for net adverse clinical events, including cardiac death, heart attacks, vessel revascularization, stroke, and significant bleeding. Researchers will assess safety and effectiveness through clinical evaluations and follow-ups. Participants will provide a DNA sample for genotyping and attend regular visits to track their health and treatment outcomes under medical supervision.
Diagnosed with acute coronary syndrome (unstable angina, NSTEMI, or STEMI) undergoing PCI
Treated with dual antiplatelet therapy (P2Y12 inhibitors plus aspirin) for at least 3 months
Willing to provide a blood sample for CYP2C19 genetic testing
Provide written informed consent before enrollment
Have at least one complex PCI feature such as thrombotic lesion, calcified lesion needing special procedures, multivessel disease, multiple lesions or stents, total stent length 60 mm or more, bifurcation lesion with two stents, PCI for left main artery, chronic total occlusion, or bypass graft PCI
You will not qualify if you...
Known CYP2C19 genotype before randomization
Expected to stop clopidogrel or ticagrelor within the 12-month follow-up
Planned surgery within 90 days
Need oral anticoagulation therapy (e.g., for atrial fibrillation, deep vein thrombosis, or pulmonary embolism)
Recent bleeding in brain, gastrointestinal, or urogenital areas within 6 months
Active bleeding, bleeding disorders, low platelets (below 100,000/mL), or low hemoglobin (below 10 g/dL)
Severe liver problems (liver enzymes more than 3 times normal)
Kidney failure (eGFR below 15 or on dialysis)
Taking strong CYP3A4 inhibitors or inducers
Life expectancy less than 1 year
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for genetic testing and eligibility assessment
Treatment
Duration - 3 months
Participants receive dual antiplatelet therapy (ticagrelor or clopidogrel plus aspirin) starting before PCI and continuing for 3 months after PCI. They are assigned to either genotype-guided or conventional therapy groups.
Visits aligned with PCI and medication monitoring during the first 3 months
Treatment
Duration - 9 months
Participants continue monotherapy with a P2Y12 inhibitor (ticagrelor or clopidogrel) without aspirin for an additional 9 months following the initial 3 months of dual therapy.
Regular follow-up visits during monotherapy phase for up to 9 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of Heart Complications in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
Safety and Effectiveness of CYP2C19 Genotype-Guided P2Y12 Inhibitor Therapy Compared to Standard Treatment After Complex Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
European Unified Registries for Heart Care Evaluation and Randomised Trials Monitoring Heart Conditions and Treatment Quality in Italy
Using Rapid Genetic Testing of CYP2C19 to Guide Blood Thinner Treatment After Acute Ischemic Stroke or Transient Ischemic Attack
Study of Colchicine Treatment Effects on Inflammation in Adults with Acute Coronary Syndrome Using Multi-omics Analysis and Model Development
Pilot Study of Genotype-Guided Clopidogrel Monotherapy for Adults with Non-ST-Segment Elevation Acute Coronary Syndrome After Successful PCI
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial).
Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial.
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.